



LAMINAR
PHARMA



FACT SHEET
November 2020



Overview

Laminar Pharma is a **Spanish biopharmaceutical company** committed to **translational health research**. We develop oncology drugs and other “first in class” products, using our patented **Membrane Lipid Therapy (MLT)** technology.

Since 2006, we have been investigating **lipid alterations** that happen in the cell membrane, studying their relationship with various pathological processes and developing **pioneering therapeutic molecules** to improve the quality of life of people who suffer serious diseases.

We control every step of the process, with constant investment in R&D and high-quality standards. We license and supply patents to large pharmaceutical companies worldwide, under a B2B exploitation model.

We are currently in the training and networking **Pre-Market Environment (EpM)** program, promoted by BME, ‘Bolsas y Mercados Españoles’ (Spanish Stocks and Markets), as a first step towards our **entry into the MAB stock market by the end of 2020**.



Management

Pablo Escribá	CEO and Founder
Antonio González	COO Chief Operating Officer
Mario Grande	Corporate Director, Investor Liaison
María Sola	Business Development Director
Victoria Lladó	CSO Chief Scientific Officer
Paula Fernández	Research Director
Cati Ana Rosselló	Quality and Development Director
Richard Taylor	Regulatory Director
Adrian McNicholl	Director of Operations and Clinical Trials
Manuel Torres (UIB)	Neuroscience Researcher
Emilce Cano	Patents and Intellectual Property
Irene Tato	Corporate and Scientific Communications


Pipeline

We are developing molecules grouped into three therapeutic areas:

- Oncology (Brain Tumor and Pancreatic Cancer)
- Neurodegenerative Diseases (Alzheimer's)
- Infectious diseases



LAMINAR PHARMACEUTICAL'S PIPELINE



Products in red are out-licensed under a B2B exploitation model

Highlights

In 2006, the **first spin-off company of the University of the Balearic Islands** was established in Mallorca as a technology-based business project.

Laminar's initial purpose was to develop and produce innovative synthetic unsaturated fatty acid therapies for some **rare, pediatric and geriatric diseases**.

Aimed at **groups with unmet clinical needs** in oncological and neurodegenerative diseases, as well as some metabolic disorders.

Laminar Pharma is recognized for creating an **innovative scientific platform called Membrane Lipid Therapy (MLT)**.

The company is a pioneer in its therapeutic approach, based on the **synthetic design of lipid molecules** and compounds derived from oleic acid.


Today the company **patents** for synthetic fatty acids are divided into seven families, some of which have been **licensed for development** to other biotechnology companies in Spain.

In 2020, Laminar is one of the 169 national organizations that are **part of the Spanish Association of Biotechnology Companies (ASEBIO)**, specifically within the Health Biotechnology group. We are responsible for 8% of new drug developments in the Spanish pipeline of red biotechnology from the ASEBIO website (see <http://pipelines.asebio.com/red/>).

Contact Information

Irene Tato

Carretera Valldemossa km 7,4 PARC BIT
Edificio Naorte, Bloque A, 1ª planta. Puerta 3
07121 Baleares (SPAIN)
+34 657.832.016
i.tato@laminarpharma.com



FACT SHEET
November 2020



www.laminarpharma.com



@LaminarPharma